Nomura Holdings Inc. Has $2.90 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Nomura Holdings Inc. Has $2.90 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Nomura Holdings Inc. lowered its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) by 10.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 70,073 shares of the biopharmaceutical company's stock after selling 7,939 shares during the quarter. Nomura Holdings Inc.'s holdings in Ultragenyx Pharmaceutical were worth $2,901,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of the stock. Lazard Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 36.6% during the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 240 shares during the period. Chartwell Investment Partners LLC raised its stake in shares of Ultragenyx Pharmaceutical by 3.6% during the 3rd quarter. Chartwell Investment Partners LLC now owns 7,623 shares of the biopharmaceutical company's stock worth $316,000 after purchasing an additional 268 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Ultragenyx Pharmaceutical by 7.6% during the 2nd quarter. Virtus ETF Advisers LLC now owns 4,895 shares of the biopharmaceutical company's stock worth $292,000 after purchasing an additional 345 shares during the period. Signaturefd LLC raised its stake in Ultragenyx Pharmaceutical by 151.0% in the 3rd quarter. Signaturefd LLC now owns 600 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 361 shares during the period. Finally, Treasurer of the State of North Carolina raised its stake in Ultragenyx Pharmaceutical by 1.3% in the 3rd quarter. Treasurer of the State of North Carolina now owns 28,613 shares of the biopharmaceutical company's stock valued at $1,185,000 after acquiring an additional 370 shares during the period. 93.17% of the stock is currently owned by institutional investors.
Get Ultragenyx Pharmaceutical alerts:Wall Street Analysts Forecast Growth
A number of equities research analysts recently issued reports on RARE shares. Canaccord Genuity Group restated a "buy" rating and issued a $90.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 18th. Robert W. Baird boosted their price objective on Ultragenyx Pharmaceutical from $50.00 to $57.00 and gave the company an "outperform" rating in a research note on Friday, February 17th. HC Wainwright restated a "buy" rating and issued a $82.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 30th. Morgan Stanley lowered their price objective on Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an "overweight" rating on the stock in a research note on Friday, February 3rd. Finally, Credit Suisse Group restated an "outperform" rating and issued a $96.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 17th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $89.47.
Ultragenyx Pharmaceutical Trading Down 2.9 %
Shares of NASDAQ RARE opened at $38.76 on Friday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $33.36 and a 12 month high of $85.53. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of -3.83 and a beta of 0.94. The business has a 50-day moving average of $44.32 and a 200-day moving average of $42.39.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last issued its quarterly earnings data on Thursday, February 16th. The biopharmaceutical company reported ($2.16) EPS for the quarter, missing the consensus estimate of ($2.03) by ($0.13). Ultragenyx Pharmaceutical had a negative return on equity of 110.15% and a negative net margin of 194.71%. The business had revenue of $103.35 million for the quarter, compared to analysts' expectations of $105.11 million. During the same period in the previous year, the firm posted ($1.79) EPS. The firm's revenue for the quarter was up 23.9% compared to the same quarter last year. On average, analysts predict that Ultragenyx Pharmaceutical Inc. will post -7.62 earnings per share for the current year.
Insider Transactions at Ultragenyx Pharmaceutical
In other news, CAO Theodore Alan Huizenga sold 639 shares of the business's stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $43.40, for a total transaction of $27,732.60. Following the completion of the transaction, the chief accounting officer now owns 15,558 shares of the company's stock, valued at $675,217.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, EVP Camille L. Bedrosian sold 3,881 shares of the company's stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $45.25, for a total value of $175,615.25. Following the completion of the sale, the executive vice president now owns 46,720 shares of the company's stock, valued at $2,114,080. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Theodore Alan Huizenga sold 639 shares of the company's stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $43.40, for a total value of $27,732.60. Following the completion of the sale, the chief accounting officer now directly owns 15,558 shares of the company's stock, valued at approximately $675,217.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 6,940 shares of company stock valued at $310,388. 6.70% of the stock is owned by corporate insiders.
Ultragenyx Pharmaceutical Company Profile
(Get Rating)
Ultragenyx Pharmaceutical, Inc engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.
Recommended Stories
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating).
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
據HoldingsChannel.com報道,野村控股有限公司在第三季度將其持有的Ultragenyx製藥公司(納斯達克:Rare-Get Rating)的股份減持了10.2%。該公司在本季度出售了7939股後,持有這家生物製藥公司70,073股股票。截至野村控股最近提交的美國證券交易委員會申報檔案,野村控股所持Ultragenyx Pharmtics股份價值2901,000美元。
其他幾家大型投資者也買賣了該股的股票。Lazard Asset Management LLC在第一季度將其在Ultragenyx Pharmtics的股份增加了36.6%。Lazard Asset Management LLC在此期間又購買了240股,現在擁有896股這家生物製藥公司的股票,價值6.4萬美元。Chartwell Investment Partners LLC在第三季度將其在Ultragenyx製藥公司的股份增加了3.6%。Chartwell Investment Partners LLC現在擁有這家生物製藥公司7623股股票,價值31.6萬美元,在此期間又購買了268股。Virtus ETF Advisers LLC在第二季度將其在Ultragenyx製藥公司的股份增加了7.6%。Virtus ETF Advisers LLC現在擁有這家生物製藥公司4895股股票,價值29.2萬美元,在此期間又購買了345股。Signaturefd LLC在第三季度將其在Ultragenyx製藥公司的持股比例提高了151.0。Signaturefd LLC在此期間額外收購了361股,現在擁有600股這家生物製藥公司的股票,價值2.5萬美元。最後,北卡羅來納州財政部長在第三季度將其在Ultragenyx製藥公司的持股比例提高了1.3%。北卡羅來納州的一位財務主管在此期間額外購買了370股,現在擁有28,613股這家生物製藥公司的股票,價值1,185,000美元。93.17%的股票目前由機構投資者持有。
到達超大基因製藥公司警報:華爾街分析師預測經濟增長
一些股票研究分析師最近發佈了關於稀有股票的報告。Canaccel Genuity集團在1月18日星期三的一份研究報告中重申了“買入”評級,並對Ultragenyx製藥公司的股票發佈了90美元的目標價。羅伯特·W·貝爾德將他們對Ultragenyx製藥公司的目標價從50.00美元上調至57.00美元,並在2月17日星期五的一份研究報告中給出了該公司“跑贏大盤”的評級。12月30日,星期五,HC Wainwright在一份研究報告中重申了“買入”評級,並對Ultragenyx製藥公司的股票發佈了82.00美元的目標價。摩根士丹利在2月3日星期五的一份研究報告中將他們對Ultragenyx Pharmtics的目標價從100.00美元下調至95美元,並對該股設定了“增持”評級。最後,瑞士信貸集團在2月17日星期五的一份研究報告中重申了“跑贏大盤”的評級,並對Ultragenyx製藥公司的股票發佈了96.00美元的目標價。三名投資分析師對該股的評級為持有,九名分析師對該公司股票的評級為買入。根據MarketBeat的數據,該公司目前的共識評級為“適度買入”,共識目標價為89.47美元。
Ultragenyx製藥公司股價下跌2.9%
上週五,納斯達克稀有的股價開盤報38.76美元。Ultragenyx Pharmtics Inc.股價跌至33.36美元的12個月低點和85.53美元的12個月高點。該公司的市值為27.2億美元,本益比為-3.83倍,貝塔係數為0.94。該業務的50日移動均線切入位在44.32美元,200日移動均線切入位在42.39美元。
超凡藥業(納斯達克:Rare-Get Rating)最近一次發佈季度收益數據是在2月16日(星期四)。這家生物製藥公司公佈了該季度每股收益(2.16美元),低於普遍預期的(2.03美元)和(0.13美元)。Ultragenyx製藥公司的淨資產回報率為負110.15%,淨利潤率為負194.71%。該業務當季營收為1.0335億美元,高於分析師預期的1.0511億美元。去年同期,該公司公佈的每股收益為1.79美元。與去年同期相比,該公司本季度的收入增長了23.9%。分析師平均預測,Ultragenyx製藥公司本年度每股收益為7.62美元。
Ultragenyx製藥公司的內幕交易
在其他新聞方面,CAO Theodore Alan Huizenga在一筆日期為2月28日星期二的交易中出售了639股該公司股票。該股以43.40美元的平均價格出售,總成交金額為27732.60美元。交易完成後,首席會計官現在擁有15558股公司股票,價值675,217.20美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可以通過美國證券交易委員會網站。在Ultragenyx製藥公司的其他新聞中,執行副總裁卡米爾·L·貝德羅西安在3月1日星期三的一筆交易中出售了3881股該公司股票。這只股票的平均售價為45.25美元,總價值為175,615.25美元。出售完成後,執行副總裁總裁現在持有該公司46,720股股票,價值2114080美元。這筆交易是在提交給美國證券交易委員會的一份法律檔案中披露的,該檔案可以通過這個環節。此外,首席財務官西奧多·艾倫·惠曾加在2月28日星期二的一筆交易中出售了639股該公司股票。這只股票的平均售價為43.40美元,總價值為27732.60美元。出售完成後,首席會計官現在直接擁有公司股票15,558股,價值約675,217.20美元。關於這次銷售的披露可以找到這裡。在過去的90天裡,內部人士出售了6940股公司股票,價值310,388美元。6.70%的股份由企業內部人士持有。
Ultragenyx製藥公司簡介
(獲取評級)
Ultragenyx製藥公司從事用於治療遺傳病的新產品的識別、收購、開發和商業化。其產品包括Crysvita、Mepsevii、Dojolvi和Evkeeza。該公司由Emil D.Kakkis於2010年4月創立,總部設在加利福尼亞州諾瓦託。
推薦故事
- 免費獲取StockNews.com關於Ultragenyx製藥公司的研究報告(Rare)
- SVB金融崩潰對美國銀行意味著什麼
- 市場回顧周-3/6/3/10
- 2個近海鑽探公司將大賺一筆
- 未來有望實現兩位數上漲的三隻史泰博股票
- 投資者能信任消費者來提升美國戶外品牌嗎?
想看看其他對沖基金持有的稀有資產嗎?訪問HoldingsChannel.com獲取Ultragenyx製藥公司的最新13F備案和內幕交易(納斯達克:Rare-Get Rating)。
獲得《Ultragenyx藥學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Ultragenyx製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧